Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Tao-Yuan, Taiwan.
Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):20-9. doi: 10.1002/pds.2010. Epub 2010 Dec 1.
To examine the potentially inappropriate prescription of thiazolidinediones (TZD).
Data on TZD prescriptions were collected from Taiwan's National Health Insurance dataset from 2001 to 2006. TZDs were considered inappropriately prescribed when they were prescribed to patients who were (1) under 18 years old, (2) pregnant, who had (3) type 1 diabetes, (4) severe heart failure, (5) hepatic insufficiency, or (6) renal insufficiency and taking TZD + metformin in combination. We aggregated potentially inappropriate prescriptions of TZD for each health-care institution in each month starting from March 2001, when TZD was introduced to Taiwan's market.
The potentially inappropriate prescription of TZD increased from 9.41% in 2001 to 12.50% in 2006. Prior inappropriate prescription led to a 0.06% (95%CI: 0.04-0.08) further increase in its later inappropriate prescription. Accumulated months of experience prescribing TZD was found associated with higher proportion of inappropriate prescription of TZD (0.03%, 95%CI: 0.01-0.05). However, it was negatively associated with new incidence of inappropriate prescription of TZD (-0.20, 95%CI: -0.22 to -0.18). The greater the volume of prior TZD prescription (-0.87%, 95%CI: -0.93 to -0.81) and the greater the number of accumulated months since adoption (-0.14%, 95%CI: -0.16 to -0.12), the greater the decrease in rates of new inappropriate prescriptions.
Along with the quick penetration of the new DM drug came an increased possibility that it would be prescribed inappropriately, a trend that persisted over time.
考察噻唑烷二酮类药物(TZD)潜在不合理处方的情况。
数据来源于 2001 年至 2006 年台湾全民健康保险数据库中 TZD 的处方记录。当 TZD 被开给以下患者时,即视为不合理处方:(1)年龄小于 18 岁,(2)孕妇,(3)1 型糖尿病患者,(4)严重心力衰竭患者,(5)肝功能不全患者,或(6)肾功能不全患者,且同时服用 TZD 和二甲双胍。我们从 2001 年 3 月 TZD 进入台湾市场开始,每月汇总各医疗机构 TZD 的潜在不合理处方量。
2001 年 TZD 的不合理处方率为 9.41%,至 2006 年增至 12.50%。先前不合理处方会导致后续不合理处方率额外增加 0.06%(95%CI:0.04-0.08)。TZD 处方经验的累积月数与 TZD 不合理处方的比例呈正相关(0.03%,95%CI:0.01-0.05)。然而,它与 TZD 新发生不合理处方的比例呈负相关(-0.20,95%CI:-0.22 至-0.18)。之前 TZD 处方量越大(-0.87%,95%CI:-0.93 至-0.81),TZD 上市后累积月数越多(-0.14%,95%CI:-0.16 至-0.12),新发生不合理处方的比例越低。
随着新型糖尿病药物的迅速普及,其不合理处方的可能性增加,这种趋势持续存在。